Financial Operational Delivering a step change in commercial execution with growth across the portfolio. Supporting growth in operating profit and earnings per share (EPS). • A strong year with NPATA attributable to equity holders of US$2.91 billion for the year ended 30 June 2024, up 11% on a reported currency basis when compared to the prior comparable period. • Strong growth in Immunoglobulins portfolio, up 20% at constant currency. • CSL Seqirus revenue up 4% at constant currency driven by strong growth in FLUAD®. • CSL Vifor well positioned for an evolving iron market. • Record levels of plasma collections. • 110 million influenza vaccine doses distributed by CSL Seqirus. • Base fractionation capacity completed at Broadmeadows and Marburg. • Participated in 479 regulatory inspections of our manufacturing facilities and plasma collection centres. • Vifor cost synergies delivered ahead of expectation. • Rika rollout in 84 centers as at 30 June 2024, and on track for completion by the end of FY2025. I-Nomogram gained FDA clearance with clinical trials showing an average 10% increase in the volume of plasma collected per donation with an average collection time of less than 35 minutes. Continuing to support life and data scientists with automation, artificial intelligence and stronger data and analystics programs. Performance US$14.8b Group revenue US$2.91b NPATA attributable to equity holders US$2.64 Total ordinary dividends 3.8m CSL Plasma app downloads to date 84 Centres Rika Plasma Donation System™ Rollout 2024 2023 13.3 2024 2023 2.36 27% on 2023 2024 2023 3m NPATA 11% on 2023 at reported currency 2024 2023 2.61 6 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3